New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors-Reference-Cited by-同舟云学术

New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors

Published:2013-12-06 Issue:1 Volume:2013 Page:131-137
ISSN:1520-4391
Container-title:Hematology
language:en
Short-container-title:

Author:

Advani Anjali S.¹²

Affiliation:

1. Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, and

2. Cleveland Clinic Lerner College of Medicine, Cleveland, OH

Abstract

AbstractThe prognosis of adult acute lymphoblastic leukemia (ALL) remains poor and novel treatment strategies are needed. Antibody-based therapies represent such an approach. ALL cells express various surface antigens that are targets for monoclonal antibodies. This review focuses on 4 major classes of antibody therapy: (1) naked antibodies, (2) T-cell-engaging bispecific single-chain antibodies, (3) immunoconjugates/immunotoxins, and (4) chimeric antigen receptors. Preclinical and clinical data are reviewed. This area of research represents an exciting new approach to help improve the outcome of this disease. Several clinical trials are currently incorporating this therapy in the treatment of newly diagnosed and relapsed adult ALL patients.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/hematology/article-pdf/2013/1/131/1250416/bep00113000131.pdf

Reference38 articles.

1. Southwest Oncology Group Study S0530:a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia;Advani;Br J Haematol,2010

2. Response to high dose cytarabine (HIDAC) as first salvage for relapsed acute lymphocytic leukemia in patients receiving HIDAC as initial therapy [abstract];Advani;Blood (ASH Annual Meeting Abstracts),2011

3. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia;Kantarjian;J Clin Oncol,2012

4. Inotuzumab ozogamicin, an anti-CD22-calechiamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study;Kantarjian;Lancet Oncol,2012

5. Novel therapeutic approaches for acute lymphoblastic leukemia;Litzow;Hematol Oncol Clin North Am,2011

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody;Frontiers in Immunology;2022-08-31

2. Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy;Molecular Therapy - Oncolytics;2021-06

3. Molecular detection of fusion oncogenes in zambian patients with acute lymphoblastic leukemia;International Journal of Applied and Basic Medical Research;2020

4. An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts;Blood;2017-09-28

5. Leukaemia;TNM Online;2017-02-26